Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 275 Carcinoma, Intraductal, Noninfiltrating 25 Breast Carcinoma In Situ 21 Neoplasm Metastasis 14 Neoplasms 13 Breast Neoplasms, Male 12 Ovarian Neoplasms 10 Inflammatory Breast Neoplasms 7 Glioblastoma 6 Endometrial Neoplasms 6 Prostatic Neoplasms 5 Central Nervous System Neoplasms 5 Gliosarcoma 4 Fallopian Tube Neoplasms 4 Breast Cancer Female 4 Brain Neoplasms 4 Recurrence 3 Obesity 3 Hot Flashes 3 Glioma 3 Carcinoma, Ovarian Epithelial 3 Carcinoma, Ductal, Breast 3 Breast Diseases 3 Astrocytoma 3 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Sleep Wake Disorders 2 Sarcoma 2 Pancreatic Neoplasms 2 Oligodendroglioma 2

Interventions

Nivolumab 20 Ipilimumab 10 Surveys and Questionnaires 7 Paclitaxel 7 linrodostat 6 Standard of Care 6 Sirolimus 5 Gemcitabine 5 Bevacizumab 5 temsirolimus 4 relatlimab 4 Pemetrexed 4 Interviews as Topic 4 Docetaxel 4 Carboplatin 4 ARRY-334543 4 Vorinostat 3 Erlotinib Hydrochloride 3 Dasatinib 3 Cetuximab 3 regorafenib 2 olaparib 2 apatinib 2 anlotinib 2 abemaciclib 2 Trastuzumab 2 Sunitinib 2 Sorafenib 2 Olanzapine 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Cancer × Tamoxifen × Clear all

NCT01393990 2020-03-24

A Study of LY2228820 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed

89 enrolled 30 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡